Carlyle Group Inc.

Institutional investor · Portfolio as of Q2 2026

Top Holdings19 positions

Checking export access…
Activity:
MDLN

Medline Inc.

187.1M$7.4B73.8%$42.00-18.83%
3 qtrssince 2025-Q4
Unchanged
0
SARO

StandardAero, Inc.

84.6M$2.5B25.3%$27.16-7.10%
7 qtrssince 2024-Q4
Unchanged
0
PHAT

Phathom Pharmaceuticals, Inc.

3.5M$37.9M0.4%$8.29-30.79%
14 qtrssince 2023-Q1
Unchanged
0
INVH
INVH
REIT

Invitation Homes Inc.

662,900$20M0.2%$27.14-2.00%
14 qtrssince 2023-Q1
Decreased
0
PONY
PONY
ADR

Pony AI Inc.

2.4M$16.4M0.2%$14.35-68.29%
7 qtrssince 2024-Q4
Unchanged
0
GETY

GETTY IMAGES HOLDINGS INC

6.2M$5.4M0.1%$5.55-99.71%
15 qtrssince 2022-Q4
Unchanged
0
SP

Spruce Biosciences, Inc.

38,620$2.1M0.0%$8.95+378.32%
4 qtrssince 2025-Q3
Unchanged
0
SPWR

SunPower Inc.

2.3M$1.6M0.0%$0.82-72.33%
12 qtrssince 2023-Q3
Increased
44
ACET

Adicet Bio, Inc.

184,295$1.6M0.0%$8.42-62.35%
3 qtrssince 2025-Q4
Unchanged
0
FWRD

Forward Air Corporation

107,214$1.4M0.0%$24.54-25.02%
5 qtrssince 2025-Q2
Unchanged
0
OKUR

OnKure Therapeutics, Inc.

269,895$1.2M0.0%$8.60-70.93%
7 qtrssince 2024-Q4
Unchanged
0
DNUT

Krispy Kreme, Inc.

340,748$1.2M0.0%$14.92-78.08%
10 qtrssince 2024-Q1
Unchanged
0
QTTB

Q32 Bio Inc.

60,363$769,0200.0%$17.04-48.59%
10 qtrssince 2024-Q1
Decreased
0
REPX

Riley Exploration Permian, Inc.

16,092$530,3870.0%$32.30+45.30%
1 qtr
New
37
NBIS

Nebius Group N.V.

1,846$509,8100.0%$276.17-45.09%
1 qtr
New
36
HOOD

Robinhood Markets, Inc.

4,733$474,6250.0%$109.42-21.70%
3 qtrssince 2025-Q4
Increased
35
JSPR

Jasper Therapeutics, Inc.

1.1M$448,8660.0%$29.36-98.37%
10 qtrssince 2024-Q1
Unchanged
0
NABL

N-able, Inc.

93,732$343,9960.0%$13.07-61.44%
10 qtrssince 2024-Q1
Unchanged
0
METC

Ramaco Resources, Inc.

21,743$287,6670.0%$13.23-49.06%
1 qtr
New
35
$10B
AUM
19
Positions
Q2 2026
Filing
HI rating · 1.5/5
Quarterly 13F Value Change
Reported 13F value ($B)
Reported 13F values and quarter-over-quarter reported value changes; not investment returns.
QuarterReported value in US dollarsReported value change
2025-Q1$3,803,733,001-8.32644246964%
2025-Q2$5,032,012,38532.2914196048%
2025-Q3$4,337,675,517-13.7983934632%
2025-Q4$13,566,904,392212.76900125%
2026-Q1$10,619,090,498-21.7279772071%
2026-Q2$10,000,861,951-5.82185966978%
Activity profile
$ moved · Q2'26
New6%Increased6%Decreased45%Exited43%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 1.8 years
<1Q5%1-4Q16%1-2Y37%2Y+42%

Carlyle Group Inc. manages $10B across 19 positions as of Q2 2026. Top holdings: MDLN (73.8%), SARO (25.3%), PHAT (0.4%). Fund DNA: Concentrated Value. HoldingsIntel Score: 1.5/5.0.

Q2 2026 Summary

Added REPX, NBIS and METC; exited CUBE, HTFL, SYRE and 1 more; increased 2, led by SPWR (+1.9M shares); trimmed 2, led by QTTB (−1M shares). Top move: SPWR (INCREASED, conviction 44). Portfolio: $10.0B across 19 positions.

Top holdings by portfolio weight

Total AUM$10B
MDLN73.78%
SARO25.30%
PHAT0.38%
INVH0.20%
PONY0.16%
GETY0.05%
SPRB0.02%
SPWR0.02%
ACET0.02%
FWRD0.01%
Other0.01%

Portfolio allocation by GICS sector

Sectors9
Healthcare74.22%
Industrials25.31%
Real Estate0.20%
Technology0.18%
Communication Services0.06%
Consumer Defensive0.01%
Energy0.01%
Financial Services0.00%
Basic Materials0.00%

Behavioral investing profile

Checking access…
Concentrated Value- primarily Healthcare, Industrials
Compare DNA across all funds
7-dimension, SEC 13F-derived research score
Below Average(1.5 / 5.0)
Holdings P&L11
Conviction60
Concentration100
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

No active accumulation streaks detected for this filer.

Streaks require 2+ consecutive quarters of increased positions in the most recent period.

Famous Investors' Portfolios

What the most-followed managers hold, and what they bought and sold each quarter.

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Verify source filings on SEC EDGAR

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used